In a bold move to protect its shareholders and maintain integrity in the market, Scilex Holding Company has sent official letters to both the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA), highlighting the illegal manipulation of its common stock. As an innovative revenue-generating company focused on non-opioid pain management products, Scilex is determined to expose and combat any fraudulent activities that hinder the company’s growth and damage investor confidence.
Scilex Holding Company, traded on the Nasdaq under the ticker symbol SCLX, is recognized for its commitment to acquiring, developing, and commercializing advanced pain management solutions for both acute and chronic pain. With its primary focus on non-opioid alternatives, the company aims to address the growing concerns surrounding the opioid crisis by offering safer and more effective pain management options.
In an earlier announcement, Scilex revealed its plan to cap out-of-pocket costs for commercially insured patients. This move aims to ensure greater affordability and accessibility to Scilex’s product portfolio, which includes breakthrough solutions for postherpetic neuralgia pain (ZTlido), migraines (ELYXYB), and gout flare prophylaxis (Gloperba). By limiting costs to a maximum of $25 per month and even providing some eligible patients with a $0 payment option, Scilex is revolutionizing the pain management landscape and prioritizing patient well-being.
Moreover, Scilex Holding Company recently responded to queries from Health Canada’s Office of Patented Medicines and Liaison (OPML) regarding the composition of ELYXYB, as part of the approval process for acute migraine treatment. This engagement demonstrates Scilex’s commitment to transparency and regulatory compliance as the company seeks to widen its global reach and offer its revolutionary pain management solutions to patients in Canada.
With a solid foundation in developing non-opioid alternatives and a strong emphasis on patient affordability and accessibility, Scilex Holding Company continues to lead the way in the pain management sector. By taking legal action against market manipulation, introducing innovative cost-saving initiatives, and engaging with regulatory bodies, Scilex establishes its steadfast commitment to enhance the lives of those suffering from acute and chronic pain.
In conclusion, Scilex Holding Company’s proactive measures aim to combat illegal market manipulation, ensure patient access to affordable pain management solutions, and maintain transparency within the industry. Through these endeavors, Scilex consistently strives to fulfill its mission of transforming pain management and improving the quality of life for millions of patients worldwide.
Comments